BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hussain M, Lok AS. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat. 1999;6:183-194. [PMID: 10607230 DOI: 10.1046/j.1365-2893.1999.00160.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, Lagget M, Paganin S, Fadda M, Niro G. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281-287. [PMID: 15274664 DOI: 10.1111/j.1365-2036.2004.02073.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
2 Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31:1318-1326. [PMID: 10827158 DOI: 10.1053/jhep.2000.7296] [Cited by in Crossref: 157] [Cited by in F6Publishing: 156] [Article Influence: 7.5] [Reference Citation Analysis]
3 Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WE 4th, Gerin JL, Tennant BC. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. 2004;63:115-121. [PMID: 15302140 DOI: 10.1016/j.antiviral.2004.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
4 Tse KC, Yung S, Tang C, Yip TP, Chan TM. Management of hepatitis B reactivation in patients with lupus nephritis. Rheumatol Int 2009;29:1273-7. [PMID: 19159933 DOI: 10.1007/s00296-008-0823-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Paik YH, Chung HY, Ryu W, Lee KS, Lee JS, Kim JH, Lee CK, Chon CY, Moon YM, Han K. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. Journal of Hepatology 2001;35:92-8. [DOI: 10.1016/s0168-8278(01)00065-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
6 Delaney WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother. 2001;45:1705-1713. [PMID: 11353615 DOI: 10.1128/aac.45.6.1705-1713.2001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
7 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. [PMID: 15328117 DOI: 10.1128/aac.48.9.3498-3507.2004] [Cited by in Crossref: 407] [Cited by in F6Publishing: 115] [Article Influence: 23.9] [Reference Citation Analysis]
8 Lau GKK, Leung Y, Fong DYT, Au W, Kwong Y, Lie A, Hou J, Wen Y, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30. [DOI: 10.1182/blood.v99.7.2324] [Cited by in Crossref: 157] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
9 Shi M, Fu J, Shi F, Zhang B, Tang Z, Jin L, Fan Z, Zhang Z, Chen L, Wang H. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol. 2009;132:43-54. [PMID: 19328038 DOI: 10.1016/j.clim.2009.03.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
10 Liaw Y. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B: Management of YMDD mutations. Journal of Gastroenterology and Hepatology 2002;17:S333-7. [DOI: 10.1046/j.1440-1746.17.s3.23.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
11 Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antivir Chem Chemother. 2002;13:143-155. [PMID: 12448687 DOI: 10.1177/095632020201300301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000;32:1145-1153. [PMID: 11050068 DOI: 10.1053/jhep.2000.19622] [Cited by in Crossref: 144] [Cited by in F6Publishing: 134] [Article Influence: 6.9] [Reference Citation Analysis]
13 Liberek A, Szaflarska-Popławska A, Korzon M, Łuczak G, Góra-Gebka M, Łoś-Rycharska E, Bako W, Czerwionka-Szaflarska M. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-6. [PMID: 16688835 DOI: 10.3748/wjg.v12.i15.2412] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
14 Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002;46:2525-2532. [PMID: 12121928 DOI: 10.1128/aac.46.8.2525-2532.2002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
15 Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281-1285. [PMID: 12952220 DOI: 10.1080/1042819031000083343] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lee AJ, Lee CH, Jeon CH. Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea. Ann Lab Med 2014;34:230-4. [PMID: 24790911 DOI: 10.3343/alm.2014.34.3.230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
17 Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393-399. [PMID: 12431200 DOI: 10.1046/j.1365-2893.2002.00388.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
18 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Doo E, Liang T. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-8. [DOI: 10.1053/gast.2001.22454] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
20 Uhm JE, Kim K, Lim TK, Park B, Park S, Hong YS, Lee SC, Hwang IG, Koh KC, Lee MH, Ahn JS, Kim WS, Jung CW, Kang WK. Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2007;13:463-8. [DOI: 10.1016/j.bbmt.2006.11.019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
21 Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-34. [PMID: 12354872 DOI: 10.1128/JCM.40.10.3729-3734.2002] [Cited by in Crossref: 111] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
22 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
23 Ding F, Miao XL, Li YX, Dai JF, Yu HG. Mutations in the S gene and in the overlapping reverse transcriptase region in chronic hepatitis B Chinese patients with coexistence of HBsAg and anti-HBs. Braz J Infect Dis 2016;20:1-7. [PMID: 26613893 DOI: 10.1016/j.bjid.2015.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Sheu MJ, Kuo HT, Lin CY, Koay LB, Lee C, Chen JJ, Tang LY, Tsai SL. Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited. Eur J Gastroenterol Hepatol 2009;21:447-51. [PMID: 19190496 DOI: 10.1097/MEG.0b013e3283131389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Chan TM, Tse KC, Tang CSO, Lai KN, Ho SKN. Prospective Study on Lamivudine-Resistant Hepatitis B in Renal Allograft Recipients. Am J Transplant 2004;4:1103-9. [DOI: 10.1111/j.1600-6143.2004.00467.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
26 Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-1749. [PMID: 14724827 DOI: 10.1053/j.gastro.2003.09.026] [Cited by in Crossref: 325] [Cited by in F6Publishing: 271] [Article Influence: 19.1] [Reference Citation Analysis]
27 Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718-1726. [PMID: 19073746 DOI: 10.1128/jvi.02011-08] [Cited by in Crossref: 126] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
28 Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6:268-274. [PMID: 18328434 DOI: 10.1016/j.cgh.2007.12.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
29 Galati G, De Vincentis A, Vespasiani-Gentilucci U, Gallo P, Vincenti D, Solmone MC, Dell'Unto C, Picardi A. Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol 2014;14:94. [PMID: 24885182 DOI: 10.1186/1471-230X-14-94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Liaw YF. The current management of HBV drug resistance. J Clin Virol. 2005;34 Suppl 1:S143-S146. [PMID: 16461216 DOI: 10.1016/s1386-6532(05)80025-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
31 Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant. 2010;24:207-212. [PMID: 19758269 DOI: 10.1111/j.1399-0012.2009.01090.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
32 Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE, Xiong S, Gerin JL, Tennant BC. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005;49:2720-2728. [PMID: 15980342 DOI: 10.1128/aac.49.7.2720-2728.2005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
33 Fung SK, Fontana RJ. Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease 2006;10:275-302. [DOI: 10.1016/j.cld.2006.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]